This Randomized, Placebo Controlled Trial Will Investigate The Efficacy And Safety Of Two Doses Of Rifamycin-SV Compared To Placebo
Dublin – December 12, 2017 – Cosmo Pharmaceuticals N.V. (SIX: COPN) today announced that the first patient has been randomized in its phase II clinical trial of Rifamycin SV for diarrhoea predominant Irritable Bowel Syndrome (IBS-D). This proof of concept study will investigate if Rifamycin SV tablets can relieve the abdominal pain and diarrhoea experienced by these patients compared to placebo treatment.
“We are excited to achieve this important milestone, that will contribute to expand our Rifamycin SV franchise to new indications” said Alessandro Della Chà, Chief Executive Officer of Cosmo Pharmaceuticals.
About the trial
This randomized, placebo controlled trial will investigate the efficacy and safety of two doses of Rifamycin-SV compared to placebo. The study will include three treatment arms; 600mg Rifamycin SV twice daily, 600 mg Rifamycin SV three times daily or placebo for a period of 2 weeks. Subjects must meet the established Rome IV diagnostic criteria for IBS-D before being randomized. The study will investigate the lasting treatment effects following a 2-week course of treatment during a 3-month follow up period. The primary endpoint will be the proportion of subjects who achieve adequate relief from both abdominal pain and diarrhoea. Relief of abdominal pain is defined for the trial by a decrease of at least 30% in the weekly average pain score, and a 50% or more reduction in the number of days per week with diarrhoea. These will be patient-reported outcomes using a personal electronic diary. The study will also investigate effects on patient reported bloating symptoms, frequency, feelings of urgency, and impact on Quality of Life, assessed by questionnaire. The trial will be conducted at 25 sites in Western Europe and will recruit 342 subjects, who will be randomized 1:1:1 into each of the 3 possible treatment arms.
Irritable Bowel Syndrome (IBS-D)
IBS is a very common functional bowel disorder that can result in abdominal pain, bloating, and altered bowel function (diarrhoea, constipation, or both). IBS-D is a subtype of the disorder characterised by being symptomatically diarrhoea predominant. Estimates worldwide vary, but prevalence is high. Worldwide prevalence has been estimated at 10-20% for IBS, and up to 20% of the US population is affected by IBS. Studies report IBS frequently occurs in young adulthood, a key life period for education, establishing careers and establishing a family. The changes in bowel habit in IBS-D are frequently associated with a general physical malaise, and psychological disturbances such as panic attacks and/or generalised anxiety or mood disorders, although the link between IBS-D and these conditions is unclear.
Depending on severity, IBS-D can have a significant impact on quality of life, and healthcare costs can be high. Many sufferers of IBS-D never seek medical help. There is therefore a significant unmet medical need for more effective IBS-D treatments.
The bacterial overgrowth theory of IBS-D suggests that the excessive coliform bacteria in the small bowel give rise to the symptoms of IBS-D. The bacteria associated with overgrowth are of the colonic types, gram negative aerobes and gram-negative anaerobes that ferment carbohydrate into gas. A range of broad spectrum antibiotics including tetracycline, amoxicillin/clavulanate, metronidazole, and various fluoroquinolones have been used to reduce bacterial overgrowth and treat IBS-D. However, these compounds frequently have systemic side effects. There is growing interest in the role of altered bacterial flora contributing to the development of IBS, and the role of non-absorbable Ansamycin antibiotics in treating IBS-D.
Rifamycin SV has a wide spectrum of activity against the microbes implicated in bacterial overgrowth. Significantly, it is non-absorbed (minimal systemic side effects) and has a low resistance profile.
Cosmo is conducting this clinical study to test the safety and efficacy of Rifamycin SV, coupled with the MMX® drug delivery technology in the treatment of IBS-D.
About Cosmo Pharmaceuticals
Cosmo is a specialty pharmaceutical company that aims to become a global leader in the field of optimized therapies for selected Gastrointestinal Disorders and Endoscopic Procedures. The Company’s proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as Ulcerative Colitis and Crohn’s Disease, and Colon Infections. In addition, the Company has developed a medical device for polyp and adenoma excision and is has completed clinical trials of formerly LuMeBlue™, a diagnostic drug for the detection of colon cancer as well as new chemical entities that are being developed by the associate company Cassiopea S.p.A. for the topical treatment of skin diseases. Cosmo’s MMX® products that have reached the market are Lialda®/Mezavant®/Mesavancol®, a treatment for IBD that is licensed globally to Giuliani and Shire Limited and Uceris®, the first glucocorticosteroid indicated for the induction of remission in active, mild to moderate Ulcerative Colitis, licensed in US to Santarus/Salix/Valeant and in the Rest of the World to Ferring as Cortiment®. Cosmo’s proprietary MMX® technology is at the core of the Company’s product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy. The technology is designed to deliver active ingredients in a targeted manner in the colon. For further information on Cosmo, please visit the Company’s website: www.cosmopharma.com
Contact
John Manieri, Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 (1) 8170 370
jmanieri@cosmopharma.com
Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements.
This communication is not an offer of securities of any issuer. Securities may not be offered or sold in the United States absent registration or an exemption from the registration requirement of the US Securities Act of 1933.
This press release constitutes neither an offer to sell nor a solicitation to buy securities and it does not constitute a prospectus within the meaning of article 652a and/or 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange or any similar document. The offer will be made solely by means of, and on the basis of, a securities prospectus to be published. An investment decision regarding the securities to be publicly offered should only be made on the basis of the securities prospectus.
This press release is made to and directed only at (i) persons outside the United Kingdom, (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), and (iii) high net worth individuals, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order. Any person who is not a relevant person should not act or rely on this press release or any of its contents.
This press release does not constitute an “offer of securities to the public” within the meaning of Directive 2003/71/EC of the European Union (the “Prospectus Directive”) of the securities referred to in it (the “Securities”) in any member state of the European Economic Area (the “EEA”). Any offers of the Securities to persons in the EEA will be made pursuant to an exemption under the Prospectus Directive, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities.